Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study - CNBC
- Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study CNBC
- Eli Lilly says tirzepatide showed positive results in late-stage trial evaluating it as treatment for heart failure MarketWatch
- Pharmalittle: We're watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more STAT
- Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and Company